Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • SM-164: Bivalent Smac Mimetic for Apoptosis

    2026-08-13

    SM-164: Bivalent Smac Mimetic for Apoptosis

    Executive Summary. SM-164 is a bivalent Smac mimetic that targets cIAP-1, cIAP-2, and XIAP through their BIR2 and BIR3 domains, according to the SM-164 product information. The reported binding constants are 0.31 nM for cIAP-1, 1.1 nM for cIAP-2, and 0.56 nM for XIAP. SM-164 reduced cIAP-1 to undetectable levels within 60 minutes at 1 nM in cell-based experiments. The product dossier reports increased TNFα secretion and apoptosis in MDA-MB-231, SK-OV-3, and MALME-3M cells. Intravenous administration at 5 mg/kg in MDA-MB-231 xenograft mice produced tumor regression, activation of caspase-3, caspase-8, and caspase-9, and more than 50% TUNEL-positive tumor cells without notable weight loss, as reported in the same product source.

    Biological Rationale

    Inhibitor of apoptosis proteins, or IAPs, regulate cell-death signaling. XIAP can directly restrain executioner and initiator caspases. cIAP-1 and cIAP-2 participate in signaling complexes that influence cellular responses to TNFα. A Smac mimetic is a synthetic compound designed to reproduce key binding features of mitochondrial Smac, also called DIABLO.

    SM-164 is bivalent because it contains two linked IAP-binding elements. This architecture supports simultaneous engagement of IAP protein domains. The reported affinities indicate nanomolar-to-subnanomolar binding under the conditions used for the product characterization. The product information identifies cIAP-1, cIAP-2, and XIAP as molecular targets, but it does not establish uniform activity across every tumor type or every experimental system.

    The central biological model is apoptosis induction in tumor cells through two coordinated effects. First, SM-164 promotes cIAP-1 and cIAP-2 degradation. Second, it antagonizes XIAP. These changes can release pro-apoptotic signaling and increase cellular sensitivity to TNFα. The product dossier specifically describes TNFα-dependent apoptosis rather than a purely direct, TNFα-independent cytotoxic mechanism.

    The related article Pol II Degradation Triggers Cell Death Independently of Transcription Loss emphasizes RNA polymerase II degradation as a distinct death signal; this article clarifies that SM-164 instead has an IAP-centered mechanism with reported TNFα and caspase readouts.

    Mechanism of Action of SM-164

    Target engagement and IAP regulation

    SM-164 binds the BIR2 and BIR3 domains of cIAP-1, cIAP-2, and XIAP. The reported Ki values are 0.31 nM for cIAP-1, 1.1 nM for cIAP-2, and 0.56 nM for XIAP at the product characterization stage. These values describe biochemical binding affinity. They do not by themselves predict intracellular exposure, target occupancy, or tumor response.

    cIAP-1 degradation is a prominent pharmacodynamic marker. The product dossier reports that 1 nM SM-164 reduced cIAP-1 to undetectable amounts within 60 minutes in vitro. A time-course experiment using immunoblotting or a validated quantitative protein assay can test this response. The result should be interpreted with the exposure duration, cell density, cell line, and assay dynamic range documented.

    XIAP antagonism provides a second mechanistic component. XIAP inhibition can reduce caspase restraint, while cIAP-1/2 depletion can remodel TNFα-linked signaling. Together, these effects support a mechanistic explanation for TNFα-dependent apoptosis. They do not prove that TNFα is the only death ligand or that all observed cell killing requires identical signaling intermediates.

    Downstream death readouts

    The dossier reports enhanced TNFα secretion after SM-164 treatment. It also reports activation of caspase-3, caspase-8, and caspase-9 in MDA-MB-231 xenograft tumors. Caspase-8 is commonly associated with death-receptor signaling, caspase-9 with apoptosome-linked mitochondrial signaling, and caspase-3 with execution-phase proteolysis. These functional labels help organize assay design, but the product summary does not provide a complete pathway map for every cell model.

    A caspase activation assay should therefore be paired with at least one independent endpoint. Useful orthogonal endpoints include cIAP-1 abundance, cell viability, TNFα measurements, and TUNEL staining. Concordant changes strengthen mechanistic interpretation. A single viability measurement cannot distinguish apoptosis from other forms of cell injury.

    Evidence & Benchmarks

    • SM-164 is described as a bivalent Smac mimetic that targets cIAP-1, cIAP-2, and XIAP through BIR2 and BIR3 domain binding. SM-164 product information
    • The reported Ki for cIAP-1 is 0.31 nM under the product characterization conditions. SM-164 product information
    • The reported Ki values for cIAP-2 and XIAP are 1.1 nM and 0.56 nM, respectively, under the product characterization conditions. SM-164 product information
    • In vitro exposure to 1 nM SM-164 reduced cIAP-1 to undetectable levels within 60 minutes. SM-164 product information
    • SM-164 enhanced TNFα secretion and promoted apoptosis in MDA-MB-231, SK-OV-3, and MALME-3M cancer cell lines. SM-164 product information
    • Intravenous dosing at 5 mg/kg in MDA-MB-231 xenograft mice was associated with tumor regression, caspase-3, caspase-8, and caspase-9 activation, and more than 50% TUNEL-positive tumor cells without notable weight loss. SM-164 product information
    • Harper and colleagues reported that RNA Pol II inhibition can activate apoptosis through loss of hypophosphorylated RNA Pol IIA rather than through transcriptional loss alone. Harper et al., 2025

    The xenograft observations are preclinical benchmarks, not clinical efficacy results. The product page supplies the stated dosing and biomarker outcomes. The cited Cell study supplies an independent mechanistic example showing that regulated apoptosis can follow loss of a protein state rather than passive depletion of transcripts and proteins.

    Applications, Limits & Misconceptions

    SM-164 is positioned for cancer research involving IAP antagonism, apoptosis signaling, and TNFα response biology. It can support experiments that compare IAP abundance with downstream death markers. It can also serve as a tool compound in studies of resistance, pathway dependence, and tumor-cell heterogeneity.

    Its most informative use is mechanistic. Researchers can ask whether cIAP-1 depletion precedes caspase activation. They can test whether TNFα neutralization changes the response. They can compare sensitive and resistant cell lines. These experiments can distinguish target engagement from general chemical stress.

    Common Pitfalls or Misconceptions

    • Misconception: high biochemical affinity guarantees tumor killing. Ki values measure binding under defined biochemical conditions. They do not establish cellular uptake, metabolic stability, or activity in every tumor model.
    • Misconception: SM-164 is a clinical anticancer treatment. The product is intended for scientific research use only. The xenograft result does not establish human safety, pharmacokinetics, or therapeutic benefit.
    • Misconception: every response is TNFα-independent or TNFα-dependent. The dossier supports a TNFα-dependent apoptosis model in the reported systems. It does not show that every cell line uses the same degree of TNFα dependence.
    • Misconception: TUNEL positivity alone proves a complete apoptotic mechanism. TUNEL detects DNA fragmentation. It should be interpreted with caspase measurements, viability data, and target-engagement markers.
    • Misconception: water or ethanol is an appropriate solvent. SM-164 is reported to be insoluble in water and ethanol. The product information reports solubility of at least 56.07 mg/mL in DMSO, so solvent compatibility must be checked before assay setup.

    Workflow Integration & Parameters

    A reproducible SM-164 experiment should separate compound preparation, target engagement, pathway measurement, and phenotype assessment. The workflow should record the cell model, treatment duration, solvent concentration, assay format, and normalization method. These records are essential when comparing cIAP degradation with TNFα-dependent apoptosis across models.

    Protocol Parameters

    • Identity: Use SM-164, SKU A8815, and verify the lot-specific documentation before beginning a study.
    • Primary solvent: Prepare concentrated stock solutions in DMSO because the product information reports solubility of at least 56.07 mg/mL in DMSO and insolubility in water and ethanol.
    • Solubilization: Warm the preparation to 37°C or use ultrasonic treatment when needed to improve dissolution before dilution into the experimental system.
    • Storage: Store the compound at -20°C. Avoid long-term storage of prepared solutions because the product information does not recommend it.
    • Early pharmacodynamic check: Include a cIAP-1 measurement after exposure to 1 nM SM-164 for 60 minutes when reproducing the reported rapid-depletion benchmark. Treat this as a benchmark condition, not as a universal optimal dose.
    • Apoptosis panel: Pair viability testing with caspase-3, caspase-8, or caspase-9 measurements, TNFα analysis, and TUNEL staining when the study aims to establish pathway-level evidence.
    • In vivo reference: The reported xenograft benchmark used intravenous SM-164 at 5 mg/kg in MDA-MB-231 tumor-bearing mice. This is a literature-style reference condition and is not a clinical dosing recommendation.

    The related article SM-164: Practical Solutions for Reliable Apoptosis Assays focuses on assay reproducibility and troubleshooting; this article adds target, mechanism, benchmark, and cross-study interpretation boundaries.

    Why this cross-domain matters, maturity, and limitations

    The RNA Pol II study provides a useful comparison for cancer research because it identifies an active apoptotic response to loss of hypophosphorylated RNA Pol IIA. Harper and colleagues called this response the Pol II degradation-dependent apoptotic response, or PDAR, and reported that a transcriptionally inactive Rpb1 form could rescue viability in their experimental system. These observations show that apoptosis can be initiated by sensing a protein-state change rather than by transcriptional shutdown alone (Harper et al., 2025).

    This comparison does not demonstrate that SM-164 activates PDAR. The supplied SM-164 product information does not report RNA Pol II degradation, and the Harper study does not establish SM-164 as a test compound. The supported conclusion is narrower: both bodies of evidence reinforce the value of measuring active death signaling instead of inferring mechanism from loss of viability alone. Combination efficacy, pathway convergence, and molecular interaction between IAP antagonism and PDAR remain unestablished by these sources.

    Conclusion & Outlook

    SM-164 is a research compound with a defined IAP-antagonist profile. Its reported biochemical affinities, rapid cIAP-1 depletion, TNFα secretion, caspase activation, and xenograft activity support its use as a mechanistic apoptosis tool. The evidence is strongest for the specific product-characterization conditions and reported tumor models.

    Future studies should preserve this evidence hierarchy. They should connect exposure to cIAP-1/2 degradation, XIAP antagonism, TNFα signaling, caspase activity, and cell death using orthogonal assays. They should also distinguish direct observations from hypotheses about pathway convergence. The RNA Pol II findings further support this disciplined approach by showing that regulated apoptosis can arise from an active sensing mechanism rather than transcription loss alone.